Inventiva S.A. (IVA) saw its stock price plummet 5.77% during intraday trading on Monday, following the release of disappointing quarterly financial results.
The biopharmaceutical company reported both earnings per share and revenue that fell short of analyst expectations, prompting investor concern and selling pressure.
Inventiva reported quarterly losses of $2.14 per share, missing the consensus estimate of $1.66 by 28.92%. The company's quarterly sales of $5.064 million also missed the $6.000 million estimate by 15.60%, representing a significant year-over-year decrease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments